ArticleFrontiers in pediatrics2025
Rapid-onset methimazole-induced lupus in a pediatric patient with Graves' disease: a case report and review of the literature.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graves' disease (GD) is the leading cause of autoimmune hyperthyroidism, though pediatric cases are uncommon. Methimazole (MMI) is the first-line therapy; however, drug-induced lupus erythematosus (DILE) secondary to MMI is rare and may be overlooked. We report the case of a 16-year-old girl with newly diagnosed GD who developed inflammatory polyarthritis, a diffuse pruritic maculopapular rash, and alopecia within 1 week of starting MMI (10 mg/day). Laboratory evaluation showed positive antinuclear antibodies and anti-histone antibodies, reduced complement C3 and low-normal C4, and negative anti-double-stranded DNA and extractable nuclear antigen antibodies; urinalysis was normal. MMI was discontinued and oral prednisone (20 mg/day) initiated, resulting in marked improvement within 1 week and complete symptom resolution by days 10-14. This presentation is notable for the unusually rapid onset of MMI-associated DILE in an adolescent and the presence of alopecia, a feature more typical of idiopathic systemic lupus erythematosus (SLE) than classic DILE. The case underscores the importance of maintaining a high index of suspicion for DILE shortly after antithyroid drug initiation, carefully differentiating it from idiopathic SLE using serology and clinical course, and promptly withdrawing the offending agent. Early recognition and short courses of corticosteroids can lead to rapid and complete recovery, while avoiding unnecessary investigations or prolonged morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.